Validation of metabolic tumor volume as a prognostic factor for oral cavity squamous cell carcinoma treated with primary surgery

Accounting for over 20% of all cases in North America, oral cavity squamous cell carcinoma (OCSCC) is the most common site of occurrence for head and neck mucosal cancers (HNC) [1]. Successful treatment and better prognosis has traditionally depended on tumor staging, local regional tumor extension, anatomical tumor site, histotype, lymph node involvement and locoregional disease control [2–5]. Recent developments in tumor and protein expression biomarkers have brought about the possibility of patient centered treatment options by using biomarkers to stratify patients according to risk of disease progression in order to improve survival benefits for at risk patient populations [3,4].

from #ORL via xlomafota13 on Inoreader http://ift.tt/1pOsyxx
via IFTTT